To examine the therapeutic potential of SLC7A9, control and shSLC7A9 lentiviruses were injected at multiple sites around the PDX tumours, and erastin was injected intraperitoneally on day 49 (30 mg/kg administered every 2 days; Fig. 7f and Supplementary Fig. S6c). The gene discussed is SLC7A9; the disease is neoplasm.